Is China getting its genetic data, a new area of competition between China and the us, or a new topic of criminality?

Whenever China in some areas by leaps and bounds, there will always be some firms try to buckle to China on a "thief" hat, such as a number of advanced weapon equipment research and development of breakthrough progress;
And China's hacking threat has been hyped more than once.

The United States is right to be vigilant about the strategic security of local genetic data. Similarly, China seems to have a need for systemic prevention and co-ordination in this regard.

The following is the translation of the ft.

• Research progress and China's ambitions

Genome research promises a new era of precision targeting drugs that make traditional generic drugs look like a world war ii idiot bomb.
But bespoke treatments for patients' individual genomes are still in their early stages.

Both the United States and China are actively studying the personalized treatment of diseases such as cancer, cystic fibrosis and Alzheimer's.
Last year China unveiled a $9 billion 15-year research plan that dwarfs the $215 million grant that the Obama administration has earmarked for the national institutes of health (NIH).

Since the first sequencing of the human genome in 2000, DNA science has leapt forward.
It used to take years and billions of dollars to work, and now it can be done in less than a week.
The United States is collecting genetic data from more than 1 million volunteers to automate laboratory systems to study how individual genes interact.

"The first question is data...
You need a lot of data, "says Eleonore Pauwels of the Wilson Center in Washington.

Beijing's ambitions in the sector have led some Chinese companies to take the path of takeovers - particularly in the us.
In January, for example, shenzhen's carbon cloud intelligence (iCarbonX, which combines artificial intelligence and large genetic databases to create personalized health care), invested more than $100 million in PatientsLikeMe.
The us company claims to be the world's largest personalized health network, with more than half a million people sharing medical details.
PatientsLikeMe, based in Cambridge, mass., says its data are anonymous and stored in servers in the United States.

Such data - stored in 100 GB to 1TB documents - can be used to develop new drugs.
The lab collects huge amounts of such data and then combines them with detailed data on demographics, eating habits, health and lifestyle.
Supercomputers look for patterns, identify genetic defects and provide new treatment recommendations.

• Cross-border acquisitions and global cooperation

However, the same data set can be used to develop biological weapons.
The F.B.I. first raised concerns about biomedical concerns in late 2014 and has yet to make formal policy recommendations.
The recommendations, which have a master's degree in biochemistry and molecular biology, would make it more difficult to move overseas by tightening regulations on health records.

While most senior positions in the tech sector are still vacant, Mr Yu insists that the FBI's concerns are starting to "have a bigger impact" within the government.

Outside the government, opinions differ.
"I don't think he's alarmist.
He asked questions that needed to be raised and answered, "said Ben Shobert, a senior fellow at the National Bureau of Asian Research.

But Bernard Munos, a senior fellow at the fastergo center at the Milken Institute, said the FBI's concerns were exaggerated.
"They can steal data from us," he said of his rivals. "data is a necessary but not sufficient condition.
You need smart people to extract knowledge from data and to imagine new treatments based on knowledge.
Now, the Chinese are limited in their ability to achieve that."

FBI officials are aware that science is a global effort that will wither if it is confined to national boundaries.

Without the help of Britain, Germany, France, Japan and China, for example, the Human Genome Project would take longer.
About 40 percent of biomedical scientists in the United States come from China or India, munoz said.

"Without these people, American biomedical research would be hard to work today," he says. "cooperation is an essential part."

That is why cross-border takeovers have so far been almost unopposed.
In 2013, the committee on foreign investment in the us government approved the acquisition of Complete Genomics, a Californian company, by bgi-shenzhen.
The latter sequenced more than 20,000 human genomes.

• According to the FBI's concern

Mr. Wessel, a member of the u.s.-china economic and safety assessment board, said such a deal could now be rejected.
One reason is the lack of reciprocity.
Mr Shorbert said Chinese regulations would not allow foreign companies to take genetic data out of China, even though Chinese companies have stakes in us biomedical companies.

The cfius also does not track most foreign loans, less than 10 per cent of non-controlling investments - such as the acquisition of carbon cloud intelligence - or a stake in a start-up.

"The most interesting thing at the beginning, the things that were being studied in the garage, could be infiltrated by Chinese money, which scared the FBI," rosen said.

In congress, senator John Cornyn, a republican leadership member, plans to introduce legislation that would expand the scope of foreign investment to joint ventures and other technology companies.
"The status quo of Chinese investment is unsustainable," Mr Corning said at an event at the Council on Foreign Relations in June.

• The network risk

Cross-border acquisitions are not the only risk to us genetic data.
The medical profession is notoriously vulnerable to cyber attacks.
Although most public attention has so far focused on identity theft or theft of credit card information, the patient's medical records are often more vulnerable to theft, he said.
He told the u.s.-china economic and security assessment commission in March that recent hacking incidents had involved "real infiltration and access to clinical data."

In December, hackers dived into Quest Diagnostics, which records 34,000 patient records, including lab results.
The company boasts the world's largest database of clinical laboratories.

Although there is no evidence that foreign forces to participate in this event, but California regulators announced in January and insurers Anthem settlement, said U.S. officials believe, on behalf of the Chinese government, the network hacker scored Anthem in 2014, and spent a year's time through the record of 78.8 million customers.

"Overall, healthcare is far less secure than many other sectors and sectors.
If, therefore, to resolve the actors have the power, their ability to sure enough to obtain such information, "Internet security company, mandy ong (Mandiant), vice President of Charles carma (Charles Carmakal) carr said," we just haven't met."

At the same time, national security risks loom.
The U.S. government has long invested in the defense of about 60 pathogens and 10 toxins that pose a "serious" health risk, including ebola, H1N1 and ricin.

But gene editing and a new generation of DNA sequencing technology allowed scientists to make new viruses such as weapons, perhaps including crack existing immune system or with custom pathogens resistant to existing drugs.
Some experts have warned about the use of biological weapons used to kill specific populations and even individuals.

Last year, James Clapper, director of national intelligence, put the gene-editing aimed at making new biological weapons into the country's biggest security threat.
"The risks are real," a White House science advisory panel said in November, "and will be increasingly dangerous as biotechnology becomes more complex in the years to come."

"Internal threats: scientists accused of stealing trade secrets"

Has a doctorate in biochemistry and 4 patents Xue Yu (Yu Xue) is "one of the world's top protein biochemist, prosecutors accused Xue Yu stealing trade secrets from their working for the company.

Xue Yu sitting in her office in GlaxoSmithKline (GlaxoSmithKline) - located in Pennsylvania Merion (Upper Merion) across a golf course - send confidential documents via E-mail to the accomplices suspects, at the same time to download other files in the thumb drive.

She was helping to develop a monoclonal antibody -- a self-seeking device that would carry drugs to cancer cells to slow the growth of cancer cells or kill cancer cells.
This is an early example of precision medicine, which offers a great deal of hope for the treatment of some of the more difficult diseases and the global leadership of western pharmaceutical companies.
The case highlights what U.S. officials say is China's comprehensive effort to secure U.S. technical secrets.

According to the U.S. District Court in Philadelphia (US District Court) on May 24, submit the latest complaint, accomplices suspects in China nanjing formed a company called ren's pharmaceutical co., LTD. (Renopharma Inc.) the company to sell steal confidential, including testing the step-by-step instructions, glaxosmithkline to inject a patient of protein purification process, and the experimental results.

The company, which is also facing charges, said it received Chinese government funds, low-interest loans, a tax free period and a 4,000-square-foot rent-free laboratory.

"The government at different levels has helped us a lot," the prosecutor quoted him as saying in an email. "it shows us that the path we have chosen is right."

Another said Mr Ren, who is expected to make nearly $75m in sales this year, is expected to produce "new drugs with Chinese intellectual property".

Li tao, xue yu and his equally charged twin, xue tian, pleaded not guilty.
Lucy Xi, who also works for glaxosmithkline, has yet to file a plea, and the court documents did not include a lawyer for the last defendant, Mrs May.
GSK is based in the UK.

prev:Japan has studied the transplantation of pig islet cells to diabetics(2017-08-09)

next:Can people sleep and study?(2017-08-10)